Shionogi & Co. Ltd.’s oral antiviral for COVID-19, Xocova (ensitrelvir), has been approved in Japan on its third attempt and will become the third such drug available in the country, although the first to have been developed by a domestic pharma firm.
The 3CL protease inhibitor was granted authorization by the Ministry of Health, Labour and Welfare under an urgent approval system...







